Skip To Main Content
M .G. Lebwohl on Muck Rack

M .G. Lebwohl

As seen in: Medscape, SKIN The Journal of Cutaneous Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with M .G.

Contact M .G., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials

|
By D Thaçi, A Armstrong, M .G. Lebwohl, A Blauvelt
| SKIN The Journal of Cutaneous Medicine Verified
Main Article Content Keywords bimekizumab, maintenance, efficacy, psoriasis, phase 3, clinical trial References 1. Warren RB et al. N Engl J Med 2021;385:130–141, NCT03412747 2. Reich K et al. Lancet 2021;397:487–498, NCT03370133 3. Gordon KB et al. Lancet 2021;397:475–486, NCT03410992 4. Reich K et al. N Engl J Med 2021;385:142–152, NCT03536884 5.
Open in Who Shared View Duplicates (65) Issue with article?

Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials

|
By K Reich, A Blauvelt, M .G. Lebwohl, KA Papp
| SKIN The Journal of Cutaneous Medicine Verified
Main Article Content K Reich Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf and Skinflammation® Center, Hamburg, Germany A Blauvelt Oregon Medical Research Center, Portland, Oregon, USA M Lebwohl Icahn School of Medicine at Mount Sinai, New York, New York, USA KA Papp Probity Medical Research and K Papp Clinical Research, Waterloo, Ontario, Canada P Rich Oregon...
Open in Who Shared View Duplicates (6) Issue with article?

Brodalumab as an Alternative to Ustekinumab in Psoriasis

|
By R.G. Langley, A.W. Armstrong, A. Blauvelt, M .G. Lebwohl
| Medscape Verified
Abstract and Introduction Abstract Background: Brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody, has demonstrated superior efficacy and safety over ustekinumab as induction therapy for moderate-to-severe psoriasis. Objectives: To evaluate the efficacy and safety of brodalumab through week 52 in patients who had inadequate responses to ustekinumab. Methods: A subgroup analysis of the phase III AMAGINE-2/-3 double-blind randomized controlled trials was performed.
Open in Who Shared Issue with article?
See all 4 articles